ethinyl estradiol/levonorgestrel / Generic mfg. - LARVOL DELTA

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=34 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

Comparative effectiveness of dienogest versus ethinyl estradiol/levonorgestrel combined oral contraceptive therapy in women with endometriosis-associated chronic pelvic pain. (PubMed, Front Endocrinol (Lausanne)) - "Both treatments were associated with significant improvement in endometriosis-associated pain, and the OCP group showed greater short-term pain reduction in this cohort, suggesting that the evaluated levonorgestrel/ethinyl estradiol regimen may represent a conservative treatment option, particularly in resource-limited healthcare settings. Larger multicenter longitudinal studies are warranted to further validate these findings."

Clinical • HEOR • Journal • Observational data • Endometriosis • Gynecology • Musculoskeletal Pain • Obstetrics • Pain • Women's Health

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Genetic Disorders • Obesity

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity

The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta-analysis. (PubMed, Epileptic Disord) - "Current recommendations may underestimate ASM effects on exposure to COC components, especially those in newer COCs. Greater caution is recommended with low-dose topiramate. For individuals treated with weak COC inducers without additional contraceptive means, COCs containing levonorgestrel or norethindrone might be preferable given their lower vulnerability to induction."

Journal • Retrospective data • CNS Disorders • Epilepsy

A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

TeenVIBE: Teen Vulnerability to Irritability: Brain and Estrogen Changes (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill | Initiation date: Jun 2026 ➔ Oct 2026

Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2026 ➔ Jul 2027 | Trial primary completion date: Dec 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Correlation Between Baseline Serum Testosterone Levels and Cognitive Gain Following Combined Oral Contraceptive Treatment in Patients With Polycystic Ovary Syndrome. (PubMed, Cureus) - "Baseline total serum testosterone levels were measured before starting a three-cycle course of COCs (levonorgestrel and ethinyl estradiol)...Conclusions The study did not provide sufficient evidence to conclude that baseline testosterone levels have any predictive or associative relationship with cognitive improvement following three months of COC therapy in women with PCOS. These findings suggest that cognitive gains in this population are likely influenced by factors beyond the baseline total testosterone concentrations."

Journal • Polyendocrine Metabolic Ovarian Syndrome

Ethinyl estradiol and levonorgestrel coadministration induces hypophagia and increases energy expenditure in female rats. (PubMed, Endocrinology) - "Age-specific effects on metabolic hormones and adipose depot UCP1 content were noted. Together, these results delineate an age-sensitive metabolic and endocrine profile of EE+LNG."

Journal • Preclinical • LEP

INT22854: A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants (clinicaltrialsregister.eu) - P1 | N=24 | Not yet recruiting | Sponsor: Sanofi-Aventis Recherche & Developpement

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Zenagamtide, a Novel, Long-Acting, Unimolecular GLP-1 and Amylin Receptor Agonist, Does Not Impact the Pharmacokinetics of the Combined Oral Contraceptive, Levonorgestrel/Ethinylestradiol (ECO 2026) - P1 | "These results support the use of COCs when co-administered with zenagamtide without further need for additional contraceptive measures. Furthermore, no new safety findings were identified for zenagamtide. Conflicts of interest: MBNG, SG and CW are employees of Novo Nordisk A/S."

PK/PD data • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus

Cagrilintide Does Not Affect the Exposure of the Combined Oral Contraceptive Ethinyloestradiol/Levonorgestrel or Gastric Emptying as Measured by the Paracetamol Absorption Test (ECO 2026) - P1 | "Introduction: Cagrilintide is a long-acting amylin analogue that is under development as a monotherapy for the treatment of overweight and obesity, and in a fixed-dose combination with semaglutide, a glucagon-like peptide-1 receptor agonist, for the treatment of overweight and obesity as well as type 2 diabetes. In our study, cagrilintide did not lead to clinically relevant reductions in exposure to EE or LN, indicating that cagrilintide is suitable for concomitant use with OCs. Cagrilintide also did not result in any clinically relevant delay in gastric emptying, assessed indirectly via PARA absorption. Cagrilintide was well tolerated and no new safety findings were observed."

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Real world pharmacovigilance assessment of drug related perinatal depression risks. (PubMed, Front Pharmacol) - "Multi-factor analysis identified age under 26 years, weight exceeding 74 kg, and use of sodium oxybate, levonorgestrel, ethinylestradiol/etonogestrel, or lurasidone as independent risk factors for drug-related PND. The model achieved a ROC-AUC of 0.907, indicating excellent discriminatory performance. This study identified specific drugs and demographic factors associated with PND risk, offering valuable insights for pharmacovigilance and clinical medication management."

Adverse events • Journal • Real-world evidence • CNS Disorders • Depression • Mood Disorders • Psychiatry

Oral Contraceptive Failure with GLP1 and dual GLP1/GIP Therapies: A Case Report and Systematic review of incretin-COC interactions (ACOG 2026) - "We also report the unintended pregnancy of a 39-year-old G4P2012 with obesity, conceived after 4 months of weekly semaglutide despite monophasic ethinyl estradiol/levonorgestrel COC use...Progestin effects varied: semaglutide/dulaglutide showed minimal levonorgestrel (LNG) AUC change (−8% to +5%), while tirzepatide, lixisenatide, and immediate pre-COC exenatide reduced LNG Cmax by 45–66% and AUC by 18–23%... Of 372 records, 10 studies (305 participants; 7 randomized crossover trials, 3 FDA reviews) met criteria. Most enrolled healthy, premenopausal participants, 4 evaluated postmenopausal women. Ethinyl estradiol exposure was unchanged across studies."

Case report • Clinical • Review • Genetic Disorders • Obesity

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Deciphera Pharmaceuticals, LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of Elenestinib in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Blueprint Medicines Corporation | Recruiting ➔ Completed

Trial completion

Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. (PubMed, J Clin Pharmacol) - P1 | "Based on the results of the two Phase 1 studies reported here along with the results of a Phase 2 study where transaminases elevations were also noted, both Phase 1 studies were prematurely terminated along with the clinical development of lotiglipron. ClinicalTrials.gov identifiers: NCT05671653; NCT05788328."

Journal • Breast Cancer • Genetic Disorders • Obesity • Oncology • Solid Tumor • CYP2C19

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Genetic Disorders • Obesity

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity

TeenVIBE: Teen Vulnerability to Irritability: Brain and Estrogen Changes (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill

New P4 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Deciphera Pharmaceuticals, LLC

New P1 trial